Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - EQ 10MG BASE **Federal...DOSAGE - TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20560
DOSAGE - TABLET;ORAL - EQ 35MG BASE **Federal...DOSAGE - TABLET;ORAL - EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20560
DOSAGE - TABLET;ORAL - EQ 40MG BASE **Federal...DOSAGE - TABLET;ORAL - EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20560
DOSAGE - TABLET;ORAL - EQ 5MG BASE **Federal ...DOSAGE - TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20560
DOSAGE - TABLET;ORAL - EQ 70MG BASE
USFDA APPLICATION NUMBER - 20560
DOSAGE - TABLET;ORAL - EQ 70MG BASE;2,800 IU
USFDA APPLICATION NUMBER - 21762
DOSAGE - TABLET;ORAL - EQ 70MG BASE;5,600 IU
USFDA APPLICATION NUMBER - 21762
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Cerata Pharmaceuticals LLP
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Neelkanth MineChem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Direct Compression
Disintegrants & Superdisintegrants
Taste Masking
Granulation
Chewable & Orodispersible Aids
Thickeners and Stabilizers
Co-Processed Excipients
Lubricants & Glidants
Empty Capsules
Parenteral
API Stability Enhancers
Coating Systems & Additives
Solubilizers
Controlled & Modified Release
Topical
Emulsifying Agents
Rheology Modifiers
Surfactant & Foaming Agents
Film Formers & Plasticizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
47
PharmaCompass offers a list of Alendronate Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Alendronate Sodium manufacturer or Alendronate Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Alendronate Sodium manufacturer or Alendronate Sodium supplier.
PharmaCompass also assists you with knowing the Alendronate Sodium API Price utilized in the formulation of products. Alendronate Sodium API Price is not always fixed or binding as the Alendronate Sodium Price is obtained through a variety of data sources. The Alendronate Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A FOSAMAX PLUS D manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of FOSAMAX PLUS D, including repackagers and relabelers. The FDA regulates FOSAMAX PLUS D manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. FOSAMAX PLUS D API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of FOSAMAX PLUS D manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A FOSAMAX PLUS D supplier is an individual or a company that provides FOSAMAX PLUS D active pharmaceutical ingredient (API) or FOSAMAX PLUS D finished formulations upon request. The FOSAMAX PLUS D suppliers may include FOSAMAX PLUS D API manufacturers, exporters, distributors and traders.
click here to find a list of FOSAMAX PLUS D suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A FOSAMAX PLUS D DMF (Drug Master File) is a document detailing the whole manufacturing process of FOSAMAX PLUS D active pharmaceutical ingredient (API) in detail. Different forms of FOSAMAX PLUS D DMFs exist exist since differing nations have different regulations, such as FOSAMAX PLUS D USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A FOSAMAX PLUS D DMF submitted to regulatory agencies in the US is known as a USDMF. FOSAMAX PLUS D USDMF includes data on FOSAMAX PLUS D's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The FOSAMAX PLUS D USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of FOSAMAX PLUS D suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The FOSAMAX PLUS D Drug Master File in Japan (FOSAMAX PLUS D JDMF) empowers FOSAMAX PLUS D API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the FOSAMAX PLUS D JDMF during the approval evaluation for pharmaceutical products. At the time of FOSAMAX PLUS D JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of FOSAMAX PLUS D suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a FOSAMAX PLUS D Drug Master File in Korea (FOSAMAX PLUS D KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of FOSAMAX PLUS D. The MFDS reviews the FOSAMAX PLUS D KDMF as part of the drug registration process and uses the information provided in the FOSAMAX PLUS D KDMF to evaluate the safety and efficacy of the drug.
After submitting a FOSAMAX PLUS D KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their FOSAMAX PLUS D API can apply through the Korea Drug Master File (KDMF).
click here to find a list of FOSAMAX PLUS D suppliers with KDMF on PharmaCompass.
A FOSAMAX PLUS D CEP of the European Pharmacopoeia monograph is often referred to as a FOSAMAX PLUS D Certificate of Suitability (COS). The purpose of a FOSAMAX PLUS D CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of FOSAMAX PLUS D EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of FOSAMAX PLUS D to their clients by showing that a FOSAMAX PLUS D CEP has been issued for it. The manufacturer submits a FOSAMAX PLUS D CEP (COS) as part of the market authorization procedure, and it takes on the role of a FOSAMAX PLUS D CEP holder for the record. Additionally, the data presented in the FOSAMAX PLUS D CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the FOSAMAX PLUS D DMF.
A FOSAMAX PLUS D CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. FOSAMAX PLUS D CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of FOSAMAX PLUS D suppliers with CEP (COS) on PharmaCompass.
A FOSAMAX PLUS D written confirmation (FOSAMAX PLUS D WC) is an official document issued by a regulatory agency to a FOSAMAX PLUS D manufacturer, verifying that the manufacturing facility of a FOSAMAX PLUS D active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting FOSAMAX PLUS D APIs or FOSAMAX PLUS D finished pharmaceutical products to another nation, regulatory agencies frequently require a FOSAMAX PLUS D WC (written confirmation) as part of the regulatory process.
click here to find a list of FOSAMAX PLUS D suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing FOSAMAX PLUS D as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for FOSAMAX PLUS D API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture FOSAMAX PLUS D as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain FOSAMAX PLUS D and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a FOSAMAX PLUS D NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of FOSAMAX PLUS D suppliers with NDC on PharmaCompass.
FOSAMAX PLUS D Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of FOSAMAX PLUS D GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right FOSAMAX PLUS D GMP manufacturer or FOSAMAX PLUS D GMP API supplier for your needs.
A FOSAMAX PLUS D CoA (Certificate of Analysis) is a formal document that attests to FOSAMAX PLUS D's compliance with FOSAMAX PLUS D specifications and serves as a tool for batch-level quality control.
FOSAMAX PLUS D CoA mostly includes findings from lab analyses of a specific batch. For each FOSAMAX PLUS D CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
FOSAMAX PLUS D may be tested according to a variety of international standards, such as European Pharmacopoeia (FOSAMAX PLUS D EP), FOSAMAX PLUS D JP (Japanese Pharmacopeia) and the US Pharmacopoeia (FOSAMAX PLUS D USP).
